The diagnosis and treatment of advanced non-small cell lung cancer (NSCLC) have changed dramatically since the discovery of several oncogenic driver mutations [e.g., epidermal growth factor receptor (EGFR) and mesenchymal lymphoma kinase] and the advancement of research into corresponding targeted therapies (Benjamin et al. 2022). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.